Back

Perineural invasion as a candidate prognostic marker beyond AJCC 8 staging in resected duodenal adenocarcinoma: a single-center retrospective cohort study

Lian, Y.-P.; Wu, Y.-J.; Chen, X.-Y.; Luo, X.-x.

2026-07-13 oncology
10.64898/2026.07.09.26357415 medRxiv
Show abstract

Background. Duodenal adenocarcinoma (DA) is a rare gastrointestinal malignancy with limited DA-specific evidence on the prognostic role of perineural invasion (PNI) and the performance of AJCC 8th-edition staging. We described PNI, AJCC 8 discrimination, and adjuvant-chemotherapy subgroup associations in a single-center cohort. Methods. We retrospectively analyzed 51 patients with curatively resected, histologically invasive DA (2013-2025). Overall survival (OS) and disease-free survival (DFS) were estimated by Kaplan-Meier analysis; prognostic associations by Cox regression. Model discrimination was quantified by the C-index; adjuvant-chemotherapy associations were explored across pre-specified subgroups. Analyses were exploratory and hypothesis-generating. Results. Median follow-up was 34.9 months; 26 patients (51%) died and 32 (63%) recurred, with the highest recurrence frequency 6-12 months after surgery. AJCC 8 staging discriminated modestly (C-index 0.595); no adjacent stage pair differed significantly after Bonferroni correction (minimum raw pairwise P = 0.051). Among candidate factors, PNI had the largest effect estimate (univariable HR 2.08, 95% CI 0.88-4.90, P = 0.095) and the largest incremental discrimination when added to a stage + T + N base model (delta C-index +0.062; likelihood-ratio P = 0.145), exceeding the increments from tumor size (+0.046), differentiation (+0.034), and sex (+0.016). Adjuvant chemotherapy was associated with hazard-ratio reductions in PNI-positive (HR 0.19, 95% CI 0.02-1.59), stage III (HR 0.36, 95% CI 0.12-1.15), and node-positive (HR 0.36, 95% CI 0.12-1.15) subgroups; none reached statistical significance, consistent with limited power in subgroups of 8-22 patients. Conclusion. In this small single-center cohort, PNI showed the largest prognostic effect estimate among candidate variables and the largest incremental discrimination beyond AJCC 8 stage, although neither reached statistical significance and AJCC 8 discriminated only modestly. These hypothesis-generating findings - directionally concordant with larger published DA series - support formal evaluation of PNI as a stratification variable in multicenter cohorts and in individual-patient-data meta-analyses of duodenal adenocarcinoma, rather than a change in current practice.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Gut
40 papers in training set
Top 0.1%
14.7%
2
American Journal of Gastroenterology
17 papers in training set
Top 0.1%
11.6%
3
PLOS ONE
5266 papers in training set
Top 27%
6.1%
4
BMC Cancer
67 papers in training set
Top 0.3%
5.3%
5
PeerJ
308 papers in training set
Top 0.9%
5.3%
6
Cancers
213 papers in training set
Top 2%
3.9%
7
Gastroenterology
42 papers in training set
Top 0.3%
3.9%
50% of probability mass above
8
Scientific Reports
3612 papers in training set
Top 28%
3.9%
9
Journal for ImmunoTherapy of Cancer
75 papers in training set
Top 0.7%
3.3%
10
JCO Precision Oncology
14 papers in training set
Top 0.1%
3.1%
11
British Journal of Cancer
49 papers in training set
Top 0.5%
2.6%
12
European Journal of Cancer
11 papers in training set
Top 0.1%
2.1%
13
Cancer Epidemiology, Biomarkers & Prevention
20 papers in training set
Top 0.2%
2.1%
14
Cancer Medicine
26 papers in training set
Top 0.4%
2.1%
15
Journal of Cachexia, Sarcopenia and Muscle
33 papers in training set
Top 0.3%
1.9%
16
Clinical Cancer Research
64 papers in training set
Top 1%
1.7%
17
International Journal of Cancer
49 papers in training set
Top 0.7%
1.7%
18
Nature Communications
5641 papers in training set
Top 46%
1.6%
19
Molecular Cancer Therapeutics
40 papers in training set
Top 0.5%
1.6%
20
Frontiers in Oncology
103 papers in training set
Top 2%
1.3%
21
JNCI Cancer Spectrum
10 papers in training set
Top 0.2%
1.1%
22
JNCI: Journal of the National Cancer Institute
19 papers in training set
Top 0.3%
1.0%
23
JMIR Research Protocols
21 papers in training set
Top 1%
1.0%
24
Translational Oncology
21 papers in training set
Top 0.7%
1.0%
25
Frontiers in Immunology
638 papers in training set
Top 10%
0.8%
26
Journal of Translational Medicine
57 papers in training set
Top 2%
0.8%
27
Biology Methods and Protocols
61 papers in training set
Top 3%
0.6%
28
eClinicalMedicine
77 papers in training set
Top 3%
0.6%
29
PLOS Medicine
110 papers in training set
Top 4%
0.6%
30
Annals of Oncology
14 papers in training set
Top 0.3%
0.6%